Moderna Inc (NASDAQ: MRNA) on Tuesday, soared 0.33% from the previous trading day, before settling in for the closing price of $30.27. Within the past 52 weeks, MRNA’s price has moved between $29.25 and $170.47.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 662.63%. The company achieved an average annual earnings per share of -6.92%. With a float of $341.75 million, this company’s outstanding shares have now reached $386.00 million.
Let’s determine the extent of company efficiency that accounts for 5800 employees. In terms of profitability, gross margin is 52.28%, operating margin of -122.17%, and the pretax margin is -111.71%.
Moderna Inc (MRNA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Moderna Inc is 11.42%, while institutional ownership is 70.64%. The most recent insider transaction that took place on Mar 03 ’25, was worth 5,004,318. In this transaction Chief Executive Officer of this company bought 160,314 shares at a rate of $31.22, taking the stock ownership to the 9,210,686 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Director bought 31,620 for $31.76, making the entire transaction worth $1,004,251. This insider now owns 312,027 shares in total.
Moderna Inc (MRNA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -3.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.92% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.83% during the next five years compared to -42.94% drop over the previous five years of trading.
Moderna Inc (NASDAQ: MRNA) Trading Performance Indicators
Moderna Inc (MRNA) is currently performing well based on its current performance indicators. A quick ratio of 3.62 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -9.28, a number that is poised to hit -3.11 in the next quarter and is forecasted to reach -7.63 in one year’s time.
Technical Analysis of Moderna Inc (MRNA)
Looking closely at Moderna Inc (NASDAQ: MRNA), its last 5-days average volume was 8.02 million, which is a drop from its year-to-date volume of 12.39 million. As of the previous 9 days, the stock’s Stochastic %D was 9.18%. Additionally, its Average True Range was 2.48.
During the past 100 days, Moderna Inc’s (MRNA) raw stochastic average was set at 3.67%, which indicates a significant decrease from 14.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.56% in the past 14 days, which was lower than the 71.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $37.02, while its 200-day Moving Average is $74.28. However, in the short run, Moderna Inc’s stock first resistance to watch stands at $31.23. Second resistance stands at $32.08. The third major resistance level sits at $33.02. If the price goes on to break the first support level at $29.43, it is likely to go to the next support level at $28.49. Now, if the price goes above the second support level, the third support stands at $27.64.
Moderna Inc (NASDAQ: MRNA) Key Stats
Market capitalization of the company is 11.72 billion based on 385,816K outstanding shares. Right now, sales total 3,236 M and income totals -3,561 M. The company made 966,000 K in profit during its latest quarter, and -1,120 M in sales during its previous quarter.
